 TUCSON, Ariz., Feb. 26, 2021 GLOBE NEWSWIRE -- HTG Molecular Diagnostics, Inc. Nasdaq: HTGM HTG, a life science company whose mission is to advance precision medicine, today announced it has completed its feasibility testing for a planned whole transcriptome panel using the HTG EdgeSeq technology, and has released a follow-on whole transcriptome product white paper White Paper Two, regarding the performance of a prototype panel for multiple cancer indications compared to RNA sequencing RNA-Seq. HTG is developing a whole transcriptome panel using the HTG EdgeSeq technology to measure approximately 20,000 mRNA targets, with a planned research use only launch in the third quarter of 2021. 